Posts

Posted on

CIRA Canadian Shield reaches 100,000 user milestone in only 7 months

Support from Canadian Centre for Cyber Security helps protect thousands of Canadian families from cyber-threats

OTTAWA, Dec. 10, 2020 (GLOBE NEWSWIRE) — After only seven months in market, the Canadian Internet Registration Authority (CIRA) is proud to announce that more than 100,000 Canadians have chosen CIRA Canadian Shield to protect themselves and their families from malware, phishing and other cyber-attacks.

As millions of Canadians have been forced to work, learn, teach and socialize online, CIRA Canadian Shield has surpassed its first-year goal of 100,000 users in a little over half a year. In that time, the service has blocked more than 20 million malicious domains for its users and serves more than 500 million queries each day.

As Canadians prepare to welcome thousands of new internet-connected toys and smart home devices into their homes this holiday season, the best thing they can do to keep them safe and secure is to implement CIRA Canadian Shield.

Key facts

  • Since launch, CIRA Canadian Shield has experienced 100% uptime and blocked approximately one malicious domain per user every day, protecting them from cyber-attacks.
  • The Canadian Centre for Cyber Security provides CIRA Canadian Shield with its Canadian threat feed which has blocked more than 50,000 malicious domains since launch.
  • CIRA Canadian Shield has three levels of service: Private (only DNS privacy), Protected (additional malware and cyber-threat protection) and Family (additional adult content protection). To date, 82% of users have chosen the Protected service, 10% Family and 8% Private.
  • CIRA Canadian Shield is a free DNS privacy and cybersecurity service that operates on IPv4, IPv6 and the newest DNS encryption standards—DNS over HTTP (DoH) and DNS over TLS (DoT).
  • CIRA Canadian Shield is built on a combination of public and private threat feeds including those from our partners: Akamai, the Canadian Centre for Child Protection and the Canadian Centre for Cyber Security
  • To confirm CIRA’s commitment to privacy for its users, Deloitte LLP was recently contracted to conduct a full privacy audit of CIRA Canadian Shield. The audit found that “CIRA Canadian Shield service is suitably designed to support the achievement of CIRA’s privacy commitments.” Read the auditor’s report summary.

Executive quotes

“The pandemic has amplified what we knew when we began this project, Canadian households are vulnerable and lack the tools to protect themselves. With millions of Canadians now working remotely, that vulnerability now threatens not only personal data but corporate and public data and systems as well. We’re proud that CIRA Canadian Shield has been able to play a critical role in protecting Canadians online during this difficult time, and hope to bring this free service to millions more in the years ahead.”

  • Mark Gaudet, business lead, cybersecurity products, Canadian Internet Registration Authority

“Our goal at the Cyber Centre is that every Canadian can go securely online with confidence. We know that will take every Canadian doing their part. CIRA’s Canadian Shield, backed by the unique threat data from the Cyber Centre, is a great way for Canadians to take action to protect themselves. We are thrilled that so many Canadians are taking control of their online security and privacy by choosing this 100% Canadian cyber solution.”

  • Scott Jones, Head, Canadian Centre for Cyber Security

Additional resources

About the Canadian Internet Registration Authority

The Canadian Internet Registration Authority (CIRA) manages the .CA top-level domain on behalf of all Canadians. CIRA also develops technologies and services—such as CIRA DNS Firewall and CIRA Canadian Shield—that help support its goal of building a better online Canada. The CIRA team operates one of the fastest-growing country code top-level domains (ccTLD), a high-performance global DNS network, and one of the world’s most advanced back-end registry solutions.

Media contact

Spencer Callaghan
Communications Manager, CIRA
[email protected]
(613) 316-2397



Posted on

Accenture Recognized as a Leader in Everest Group’s PEAK Matrix for System Integrator Capabilities on AWS 2021

Accenture Recognized as a Leader in Everest Group’s PEAK Matrix for System Integrator Capabilities on AWS 2021

NEW YORK–(BUSINESS WIRE)–
Accenture (NYSE: ACN) is positioned as a Leader in the Everest Group PEAK Matrix® for System Integrator Capabilities on Amazon Web Services (AWS) 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005193/en/

Accenture is positioned as a Leader in the Everest Group PEAK Matrix® for System Integrator Capabilities on Amazon Web Services (AWS) 2021 (Graphic: Business Wire)

Accenture is positioned as a Leader in the Everest Group PEAK Matrix® for System Integrator Capabilities on Amazon Web Services (AWS) 2021 (Graphic: Business Wire)

According to Everest Group, Accenture is clearly differentiated, positioned highest among all service providers working with AWS, especially in overall Market Impact for adoption, portfolio mix and value delivered. Accenture is also at the top for Vision & Capability, notably scoring highest in vision, strategy, innovation and investments. In the analysis, Accenture is seen as driving large-scale and complex cloud transformation for large enterprises.

“Accenture continues to win large deals by placing heavy emphasis on innovative architecture and joint transformation initiatives with AWS through its Accenture AWS Business Group while taking commercial risks associated with business outcomes,” said Ashwin Venkatesan, vice president, Cloud and Infrastructure Services, at Everest Group. “We also learned that clients have identified strategy development, program management, migration planning, and strong collaboration with AWS as the biggest strengths for Accenture in the market.”

Everest Group also highlights Accenture’s broad AWS offerings in infrastructure, platforms, data, and next-generation segments. Everest Group acknowledges Accenture as having “one of the highest number of AWS qualifications including AWS Competency designations, AWS Partner programs, and service validations.”

“Since 2015, our unique business relationship with AWS, driven through the Accenture AWS Business Group, has provided clients with deep technical expertise, extensive AWS experience and breakthrough innovations,” said Karthik Narain, global lead, Accenture Cloud First. “Today, we’ve achieved not only market recognition, but our clients are now trusting Accenture more than ever to transform their businesses so they can operate and compete at unprecedented speed and scale. We’re truly enabling them to take advantage of the promise of technology and human ingenuity.”

For this report, Everest Group assessed end-to-end AWS capabilities of 27 IT service providers, including consulting, cloud infrastructure/design build, modernization and operations.

Accenture Cloud First provides the full stack of cloud services to help clients across every industry become “cloud-first” businesses so they can accelerate their digital transformation, innovate faster, and create differentiated, sustainable value. Powered by 70,000 cloud professionals, and a $3 billion investment over the next three years, we bring together an unmatched depth and breadth of cloud expertise, industry cloud solutions, ecosystem partner capabilities and assets that help clients realize greater value from cloud at speed and scale. Visit us at www.accenture.com/cloud.

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 506,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

Mylissa Tsai

Accenture

+1 917 452 9729

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Consulting Data Management Technology Professional Services Security Other Technology Software Other Professional Services Networks Internet Mobile/Wireless

MEDIA:

Photo
Photo
Accenture is positioned as a Leader in the Everest Group PEAK Matrix® for System Integrator Capabilities on Amazon Web Services (AWS) 2021 (Graphic: Business Wire)
Posted on

J.P. Morgan Executes Intraday Repo Transaction Using Blockchain

J.P. Morgan Executes Intraday Repo Transaction Using Blockchain

JPM Coin facilitated payment in exchange for collateral

NEW YORK–(BUSINESS WIRE)–
J.P. Morgan (NYSE: JPM) announced today it completed a live, blockchain-based intraday repo transaction. The transaction was successfully conducted between J.P. Morgan’s broker dealer and banking entity, using an in-house developed blockchain application which supported instantaneous settlement and maturity of the transaction in hours, as opposed to days.

The repo market provides a widely used form of secured financing, however, current operational limitations prevent the meaningful use of such financing to meet intraday liquidity needs. Using blockchain enables borrowers and lenders to execute shorter-term, intraday repo transactions with real-time, simultaneous transaction settlement, creating new ways to access intraday liquidity. Both collateral and cash legs of the repo transaction were settled using blockchain, with the cash leg leveraging JPM Coin.

“The current repo market has some technical inefficiencies, and we identified blockchain technology as a way to reduce our clients’ intraday risk profile,” said Scott Lucas, Head of Markets DLT, J.P. Morgan. “By deploying blockchain, we created new opportunities to streamline operational processes and accelerate settlement for repo. Our new solution will help unlock trapped pockets of liquidity for intraday use and allow for reduced risk profiles for our clients and J.P. Morgan.”

The offering will be made available in production to external counterparties in the U.S. – some of which have already simulated transactions on the new application. J.P. Morgan developed the solution and tested its viability by conducting trades between two of its affiliates, alongside successful simulations of trades with Goldman Sachs and other entities, with BNY Mellon as the triparty agent.

J.P. Morgan recently announced Onyx by J.P. Morgan, a new business unit to scale and commercialize blockchain innovation, with JPM Coin as a key offering from the suite of products, platform, and services. The intraday repo application is deployed on the platform developed and supported by Onyx and uses JPM Coin for the cash leg. “J.P. Morgan’s intraday repo application demonstrates how leveraging foundational technology built by Onyx enables new capabilities like the digital representation of securities ownership, supports unique functionality like atomic trade settlement, accelerates time-to-market, and eases effort required to get to production,” said Christine Moy, who led the work from the Onyx team.

“This is an exciting project which vividly highlights where enterprise blockchain can address a real-world problem in the financial system and we look forward to going live in early 2021,” said Mathew McDermott, Global Head of Digital Assets at Goldman Sachs.

“BNY Mellon is pleased to leverage our expertise as a critical partner for J.P. Morgan to provide much-needed collateral services to market participants looking to execute intraday repo transactions. The distributed ledger technology utilized ensures that clients are meeting their funding needs, and quickly,” said Brian Ruane, Chief Executive Officer of BNY Mellon Clearance & Collateral Management.

About J.P. Morgan’s Corporate & Investment Bank

J.P. Morgan’s Corporate & Investment Bank is a global leader across banking, markets and securities services. The world’s most important corporations, governments and institutions entrust us with their business in more than 100 countries. With $28 trillion of assets under custody and $634 billion in deposits, the Corporate & Investment Bank provides strategic advice, raises capital, manages risk and extends liquidity in markets around the world. Further information about J.P. Morgan is available at www.jpmorgan.com.

Jessica Francisco

(201) 248-4932

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Technology Other Professional Services Other Technology Finance Banking

MEDIA:

Logo
Logo
Posted on

Accenture Named a Leader in ServiceNow Services by Analyst Firm Everest Group

Accenture Named a Leader in ServiceNow Services by Analyst Firm Everest Group

NEW YORK–(BUSINESS WIRE)–
Accenture (NYSE: ACN) has been named a “Leader” in Everest Group’s inaugural report, “PEAK Matrix® for ServiceNow Services 2021.” This recognition follows the formation of Accenture Cloud First, which provides the full stack of cloud services to help clients across every industry become “cloud-first” businesses so they can accelerate their digital transformation, innovate faster, and create differentiated, sustainable value.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005109/en/

Everest Group ServiceNow Services PEAK Matrix® Assessment (Photo: Business Wire)

Everest Group ServiceNow Services PEAK Matrix® Assessment (Photo: Business Wire)

For the report, Everest Group assessed 20 IT service providers across global consulting, implementation and maintenance/support services for all aspects of the ServiceNow platform, encompassing IT workflows, employee workflows, customer workflows and custom applications. Everest Group’s PEAK Matrix® framework provides an objective, data-driven and comparative analysis of these service providers based on market impact and ability to deliver services successfully, with Accenture leading in the latter.

Among Accenture’s strengths cited in the report include:

  • Credible proof-points in executing transformational ServiceNow projects across IT service management and non-IT service management areas;
  • Investments in building frameworks and accelerators such as ACV4GOV, industry-aligned frameworks and center of excellence framework to expedite time-to-market;
  • Robust talent base for ServiceNow providers, with the largest pool of certified resources among all service providers across all certification streams;
  • Relatively higher customer satisfaction than peers over the last year with a greater number of responses, showcasing its ability to deliver end-to-end engagements;
  • And its global footprint and strong onshore-centric delivery model.

In addition, the report notes that Accenture’s “advisory services – in guiding clients for creating transformational roadmap, building strategy, and shaping the business case with expertise across ServiceNow…are well acknowledged by clients.”

“Accenture and ServiceNow have a long history of working together to help our clients reimagine their operations in the cloud, and we’ve recently reinforced our alliance with the establishment of the Accenture ServiceNow Business Group,” said Adam Burden, chief software engineer and North America Technology lead at Accenture. “This recognition by Everest Group further validates the significant cloud investments we’ve made globally to accelerate and transform companies to become cloud-first businesses. We look forward to continuing to enable our clients to operate with greater speed and scale and create sustainable value using ServiceNow technologies, as we further build our capabilities and talent expertise.”

Everest Group’s assessment is based on its annual Request for Information process, which considered investments made until May 2020, interactions with leading ServiceNow service providers, client reference checks and an ongoing analysis of the ServiceNow services market. An excerpt of “PEAK Matrix® for ServiceNow Services 2021,” is available here.

As a ServiceNow Global Elite Partner, Accenture is one of ServiceNow’s largest global go-to-market partners and winner of its Global Partner of the Year award in 2020. For more information on the Accenture ServiceNow Business Group, please visit: https://www.accenture.com/us-en/services/alliances/servicenow

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 506,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

Copyright © 2020 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

Christina McDonald

Accenture

+1 415 537 7997

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Technology Networks Data Management

MEDIA:

Photo
Photo
Everest Group ServiceNow Services PEAK Matrix® Assessment (Photo: Business Wire)
Posted on

Facedrive Health’s Contact-Tracing Technology TraceSCAN Secures Federal Certification from Innovation, Science and Economic Development of Canada (ISED)

Facedrive Health’s Contact-Tracing Technology TraceSCAN Secures Federal Certification from Innovation, Science and Economic Development of Canada (ISED)

TORONTO–(BUSINESS WIRE)–
Facedrive Inc. (“Facedrive”) (TSXV: FD) a Canadian “people-and-planet first” tech ecosystem is pleased to announce that its contact-tracing platform TraceSCAN, a unique wearable technology developed by Facedrive’s Health division, has been authorized by Innovation, Science and Economic Development Canada (ISED) – a department of the Federal Government of Canada – for listing, and is now poised to extend its contact-tracing services to wider retail audiences across Canada.

TraceSCAN is a standalone contact-tracing wearable solution built around cutting edge Bluetooth technology. TraceSCAN wearables were created to offer essential and other industries assistance in response to COVID19 through a joint effort between Facedrive Health and a group of researchers from the University of Waterloo. Following an endorsement from the Government of Ontario, issuance of a related white paper together with McCarthy Tétrault’s MT Ventures, numerous successful implementations with enterprise customers, and spiking demand for multifunctional connected health solutions, TraceSCAN has rapidly expanded its use- case scenarios into multiple business sectors such as recreation, travel, food processing, construction and other industries.

Innovation, Science and Economic Development (ISED), formerly known as Industry Canada, is the department of the Federal government responsible for (among other things) testing, auditing and certifying wireless products for use in the Canadian retail marketplace. As set by Canada’s Radiocommunication Act and Radiocommunication Regulations, wireless equipment sold or distributed in Canada is required to undergo testing in order to measure signals emitted by such equipment and ultimately keep users safe.

Having already proved successful as a preventive, reactive and analytics tool helping to slow the pandemic in enterprise settings, TraceSCAN is ready to offer its certified solution to the B2C market as the world mobilizes resources to mitigate the effects of the pandemic’s second wave .

“In line with the ESG commitment of the Facedrive ecosystem, we are committed to offering our services with people and planet’s safety as our number one priority,” said Rishard Ramez, General Manager of Facedrive Health. “The ISED certification is an important stamp of approval for us as it confirms TraceSCAN’s compliance with existing requirements to wireless equipment and enables us to penetrate the Canadian retail market in a responsible and efficient way. Moreover, we are working towards obtaining the FCC certification as we extend the TraceSCAN solution to our customers in the USA,” added Ramez.

About Facedrive

Facedrive is a multi-faceted “people-and-planet first” tech ecosystem offering socially-responsible services to local communities with a strong commitment to doing business fairly, equitably and sustainably. As part of this commitment, Facedrive’s vision is to fulfil its mandate through a number of verticals that either leverage existing technologies of the Company or project synergies with existing lines of business (the “Facedrive Verticals”). The Facedrive Verticals include its rideshare business (“Facedrive Rideshare”), sustainable e-commerce platform (“Facedrive Marketplace”), food-delivery service (“Facedrive Foods”), e-social platform (“Facedrive Social”) andits contact-tracing and sustainable health services business (“Facedrive Health”).

Facedrive Rideshare was among the first to offer a wide variety of environmentally and socially responsible solutions in the Transportation as a Service (TaaS) space, planting thousands of trees based on user consumption and offering choices between electric, hybrid and conventional vehicles (including, more recently, electric and hybrid vehicles on a subscription basis through Steer). Facedrive Marketplace offers curated merchandise created from sustainably sourced materials. Facedrive Foods offers contactless delivery of a wide variety of foods right to consumers’ doorsteps, with a focus on doing so in a socially and environmentally-conscious manner. Facedrive Social strives to keep people connected in a physically-distanced world through its HiQ and other e-socialization platforms that invite users to interact based on common interests and by offering gamification and mutual community support features. Facedrive Health strives to develop and offer innovative technological solutions to the most acute health challenges including its proprietary TraceSCAN wearable technology for contact tracing. Facedrive envisions changing the ridesharing, food delivery, e-commerce, social and health tech narratives for the better, for everyone, and is currently operational in Canada and the United States.

For more about Facedrive, visit www.facedrive.com.

Facedrive Inc.

100 Consilium Pl, Unit 400, Scarborough, ON, Canada M1H 3E3

www.facedrive.com

Forward-Looking Statements

Certain information in this press release contains forward-looking information. This information is based on management’s reasonable assumptions and beliefs in light of the information currently available to us and are made as of the date of this press release. Actual results and the timing of events may differ materially from those anticipated in the forward-looking information as a result of various factors. Information regarding our expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operate is forward-looking information. Statements containing forward-looking information are not facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements.

See “Forward-Looking Information” and “Risk Factors” in the Corporation’s Filing Statement dated August 28, 2019 for a discussion of the uncertainties, risks and assumptions associated with these statements. Readers are urged to consider the uncertainties, risks and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. We have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005428/en/

Media: Sana Srithas | [email protected]

Sayan Navaratnam

Chief Executive Officer and Director

Tel: 1-888-300-2228

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Retail Public Policy Other Health Technology Other Government General Health Other Transport Infectious Diseases Environment Public Policy/Government Transport Other Technology Specialty Public Transport Health

MEDIA:

Logo
Logo
Posted on

XOMA Announces Offering of Series A Cumulative Perpetual Preferred Stock

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”). The Company expects to grant the underwriters a 30-day option to purchase additional shares of the Preferred Stock in connection with the offering.

The Company expects to use the net proceeds of this offering to fund the segregated dividend account and the remaining net proceeds for general corporate purposes, including funding future acquisitions of milestone and royalty rights associated with drug development programs with third-party funding.

B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc., National Securities Corporation, and William Blair & Company are acting as joint book-runners for this offering. Aegis Capital Corp., Boenning & Scattergood, Inc., and Northland Capital Markets are acting as co-managers.

The offering of these securities is being made pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2018, and declared effective by the SEC on April 5, 2018. The offering will be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement relating to these securities may be obtained, when available, from the website of the SEC at http://www.sec.gov or by contacting: B. Riley Securities, Inc., 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, Attn: Prospectus Department, Email: [email protected], Telephone: (703) 312-9580.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About XOMA Corporation

XOMA has built a significant portfolio of products that are licensed to and being developed by other biotech and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional milestone and royalty rights associated with drug development programs with third-party funding.

Safe Harbor Statement
/ Explanatory Notes

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements include, without limitation, projections, predictions, expectations, or beliefs about future events or results and are not statements of historical fact, including statements regarding the terms and conditions and timing of the preferred stock offering and the intended use of proceeds. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the availability of, and participation in, financing opportunities. These and other risks are identified in our filings with the Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and in other filings subsequently made by the Company with the Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of these assets will become commercially available.

Investor contact:

Juliane Snowden
Oratorium Group, LLC
+1 646-438-9754
[email protected]

Media contact:

Kathy Vincent
KV Consulting & Management
+1 310-403-8951
[email protected]



Posted on

IIROC Trading Halt – ISOL

Canada NewsWire

VANCOUVER, BC, Dec. 10, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Isodiol International Inc.

CSE Symbol: ISOL

All Issues: Yes

Reason: Cease Trade Order

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Boral Limited – BOALY, BOALF

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Boral Limited – BOALY, BOALF

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Boral Limited (OTC: BOALY, BOALF) resulting from allegations that Boral may have issued materially misleading business information to the investing public.

On December 5, 2019, Boral disclosed that it identified financial irregularities in its North American window business, involving the misreporting of inventory levels and raw material and labor cost at the window plants, and was conducting an internal investigation into the matter.

On February 9, 2020, Boral revealed that its investigation had found inflated earnings at its North American window-making business and announced that the Company had fired the division’s vice president of finance and financial controller.

On this news, Boral’s American depositary receipt price fell $1.08 per share, or 7.83%, to close at $12.72 per share on February 10, 2020.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Boral investors. If you purchased shares of Boral please visit the firm’s website at http://www.rosenlegal.com/cases-register-1775.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

The PNC Financial Services Group Announces Fourth Quarter And Full Year Earnings Conference Call Details

PR Newswire

PITTSBURGH, Dec. 10, 2020 /PRNewswire/ — The PNC Financial Services Group, Inc. (NYSE: PNC) expects to issue financial results for the fourth quarter and full year 2020 at approximately 6:45 a.m. (ET), Friday, Jan. 15, 2021, as previously announced. PNC Chairman, President and Chief Executive Officer William S. Demchak and Executive Vice President and Chief Financial Officer Robert Q. Reilly will hold a conference call for investors the same day at 11:00 a.m. (ET).

Dial in numbers are (877) 272-3568 and (303) 223-2681 (international). The following will be accessible at www.pnc.com/investorevents: a link to the live audio webcast on the day of the conference call; presentation slides, earnings release and supplementary financial information; and a webcast replay available for 30 days. A telephone replay of the call will be available for one week at (800) 633-8284 and (402) 977-9140 (international), Conference ID 21972639.

The PNC Financial Services Group, Inc. is one of the largest diversified financial services institutions in the United States, organized around its customers and communities for strong relationships and local delivery of retail and business banking including a full range of lending products; specialized services for corporations and government entities, including corporate banking, real estate finance and asset-based lending; wealth management and asset management. For information about PNC, visit www.pnc.com.

CONTACTS                                                                                                                         

MEDIA: 

Marcey Zwiebel

(412) 762-4550
[email protected] 

INVESTORS:

Bryan Gill

(412) 768-4143
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-pnc-financial-services-group-announces-fourth-quarter-and-full-year-earnings-conference-call-details-301190369.html

SOURCE PNC Financial Services Group

Posted on

Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy

PR Newswire

PHOENIX, Dec. 10, 2020 /PRNewswire/ — Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company’s ImmCelz® product at generating what is termed in the field of immunology as “infectious tolerance.” 

Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel® protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz® administration caused generation of T regulatory cells and tolerogenic dendritic cells.  Both of these cell types have previously been described to possess ability to suppress autoimmunity.

“In 2003, Dr. Weiping Min from the University of Western Ontario and myself published a paper describing the Tolerogenic Loop, in which we were able to perform fully mis-matched cardiac transplants without need for long term immune suppression1.” Said Dr. Thomas Ichim, Chief Scientific Officer of the Company.  “We are extremely enthusiastic to discover that ImmCelz®, which is a personalized immunotherapy can induce similar biological processes and in this case suppress autoimmunity.”

Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.  

“Given that our issued intellectual property covers multi-billion dollar markets, it is critical in our development plans to establish scientific mechanisms of action. By understanding how our products work at a cellular and molecular level, we feel we have an advantage when engaging Big Pharma in discussions for licensing/partnering interactions.” Said Timothy Warbington, President and CEO of the Company.

The company intends to publish an update on the overall 2020 activities in the coming weeks.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com. 

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

Timothy Warbington, CEO 
CEO@ CreativeMedicalHealth.com

Creativemedicaltechnology.com

www.StemSpine.com

www.Caverstem.com

www.Femcelz.com

1
https://www.jimmunol.org/content/170/3/1304

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy-301190255.html

SOURCE Creative Medical Technology Holdings, Inc.